New research indicates that the eating disorder anorexia nervosa is associated with being an early riser, unlike many other disorders that tend to be evening-based such as depression, binge eating disorder and schizophrenia.
Neurocrine bags FDA approval for new ‘sprinkle’ Ingrezza formulation
Ingrezza generated $506m in revenue in Q1 2024, as per Neurocrine’s financials. Image Credit: Panchenko Vladimir / Shutterstock. The US Food and Drug Administration (FDA)
May 1, 2024